Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Targeted attack: mechanisms by which ovarian cancers suppress the immune system.

Tiper IV, Webb TJ.

Transl Cancer Res. 2016 Nov;5(Suppl 6):S1305-S1306. doi: 10.21037/tcr.2016.11.62. No abstract available.

2.

Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.

Tiper IV, Webb TJ.

Cancer Immunol Immunother. 2016 Nov;65(11):1411-1421. Epub 2016 Sep 10.

3.

Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Shissler SC, Bollino DR, Tiper IV, Bates JP, Derakhshandeh R, Webb TJ.

Immunogenetics. 2016 Aug;68(8):623-38. doi: 10.1007/s00251-016-0928-8. Epub 2016 Jul 8. Review.

4.

Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection.

Tiper IV, East JE, Subrahmanyam PB, Webb TJ.

Pathog Dis. 2016 Aug;74(6). pii: ftw063. doi: 10.1093/femspd/ftw063. Epub 2016 Jun 27. Review.

5.

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL 2nd, Oelke M, Schneck JP, Webb TJ.

Clin Cancer Res. 2016 Aug 15;22(16):4249-58. doi: 10.1158/1078-0432.CCR-15-2518. Epub 2016 Apr 13.

6.

NKT Cell Responses to B Cell Lymphoma.

Li J, Sun W, Subrahmanyam PB, Page C, Younger KM, Tiper IV, Frieman M, Kimball AS, Webb TJ.

Med Sci (Basel). 2014 Jun 1;2(2):82-97.

Supplemental Content

Loading ...
Support Center